Reading Time: 2 minutes Bayer said on Friday it was again petitioning the U.S. Supreme Court to sharply limit legal claims that its Roundup herbicide causes cancer, seeking to avoid potentially billions of dollars in damages.
Bayer renews bid for US Supreme Court to curb glyphosate cases
Bayer tells US it could halt Roundup weedkiller sales over legal risks
Reading Time: 2 minutes Bayer has told U.S. lawmakers it could stop selling Roundup weedkiller unless they can strengthen legal protection against product liability litigation.
Bayer projects improvement in 2026 after profit decline this year
Reading Time: 2 minutes Bayer on Wednesday raised the prospect of a return to earnings growth from 2026 after a decline this year, lifting its shares to a four-month high as its CEO somewhat allayed investor impatience with his turnaround efforts.
Bayer shareholders call on CEO to stem the tide of bad news
Reading Time: 2 minutes Some Bayer investors say CEO Bill Anderson should speed up turnaround efforts, including boosting efficiency and drug development, to restore confidence and revive the company's share price that hit 20-year lows after its shock warning this week.
Bayer’s shares sink to 20-year low on 2025 earnings fall forecast
Reading Time: 3 minutes Bayer said on Tuesday that weak agricultural markets mean its earnings are likely to fall further next year, sparking a sharp fall in the German company's shares and piling pressure on its CEO to deliver on his turnaround efforts.
Bayer investor Deka takes a stand against CEO in annual vote
Reading Time: 2 minutes Bayer shareholder Deka Investment said on Friday it would not join other large investors in supporting the healthcare and agriculture group's management at its annual general meeting.
Bayer confirms 2024 outlook despite slow start for agriculture, consumer health units
Reading Time: < 1 minute Bayer confirmed its full-year forecast for earnings and cash flow on Monday despite slow business at its crop science and consumer health divisions.
Bayer slashes outlook as glyphosate demand weakens further
Analysts say dry weather conditions hurt farmers' demand for seeds and pesticides
Reading Time: 2 minutes Reuters – Further deterioration in demand for glyphosate-based weed killers led Bayer BAYGn.DE to cut its full-year earnings outlook and announce a 2.5 billion euro ($2.8 billion USD) write-down on glyphosate-related assets. In an unscheduled statement late on Monday, the German drugs and pesticides maker said it was projecting 2023 earnings before interest, taxes, depreciation […] Read more
Bayer under investor pressure to speed up CEO changeover
Drug and chem firm's stock in 'crisis of trust,' investor says
Reading Time: 2 minutes Frankfurt | Reuters — A top-10 shareholder in Bayer on Tuesday called on the group’s supervisory board to replace CEO Werner Baumann quickly, adding to investor pressure to restore trust and revive the German drugmaker’s sagging share price. Despite recent improvements in the company’s agriculture business and drug development prospects, Bayer shares have been weighed […] Read more
Bayer’s agriculture unit, consumer health drive outlook hike
Reading Time: < 1 minute Frankfurt | Reuters – Agriculture and pharmaceuticals company Bayer BAYGn.DE on Thursday lifted its 2022 earnings guidance on strong demand from farmers for its seeds and crop chemicals and higher sales of consumer health products. Bayer is now targeting earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, of about 13 billion […] Read more
A message from April Stewart, Country Guide's Associate Editor
